2National Committee for Clinical Laboratory Standards.Performance standards for antimicrobial susceptibility testing.14th inform suppl.M2-A8 and M7-A6 [S].National Committee for Clinical Laboratory Standards,Wayne,PA,2004.
3Livermore D M,Winstanley T G,Shannon K P.Interpretative reading:recognizing the unusual and inferring resistance mechanisms from resistance phenotypes [J].J Antimicrob Chemother,2001,48 (Suppl S1):87.
4Veesenmeyer JL, Hauser AR, Lisboa T, et al. Pseudomonas aerug- inosa virulence and therapy : evolving translational strategies [ J ]. Crit Care Med. 2009,37 ( 5 ) : 1777.
5Campodonico VL, Gadjeva M, Paradis-Bleau C, et al. Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis [J]. Trends Mol Med,2008,14 ( 3 ) : 120.
6Breidenstein EB, de la Fuente-Nunez C, Hancock RE, Pseudo- monas aeruginosa: all roads lead to resistance [ J ]. Trends Microbiol,2011,19 ( 8 ) :419.
7Hagihara M, Kuti JL, Nicolau DP, Predicting doripenem suscepti- bility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa [ J ]. Diagn Microbiol Infect Dis, 2012, 72(3) :258.
8Bozkurt-Guzel C, Gerceker AA, In vitro pharmacodynamic proper- ties of colistin methanesulfonate and amikacin against Pseudomonas aeruginosa [ J ]. Indian J Med Microbiol, 2012,30 (1) :34.
1Zafer MM, Amin M, El Mahallawy H,et al. First report of NDM-1-producing Pseudomonas aeruginosa in Egypt [J]. Int J Infect Dis, 2014, 29C:80-81.
2Inacio HS, Bomfim MR, Fran a RO, et al. Phenotypic and Genotypie Diversity of Multidrug-Resistant Pseudomonas aeruginosa Isolates from Bloodstream Infections Recovered in the Hospitals of Belo Horizonte, Brazil[J].Chemotherapy,2014,60(1):54-62.
3CLSI. M07/A8-2012. Performance standards for antimicrobial sus- ceptibility testing[ S]. America: Clinical and Laboratory Standards Institute, 2012.
